Guardant Health Sales Rise 36% — But Its Annual Cash-Use Forecast Climbs Too
Shield screening revenue grew 180%, while higher spending accompanied an increase in the company's annual sales outlook.
Guardant Health, which makes blood and tissue cancer tests, increased its 2026 sales outlook Thursday after third-quarter revenue rose 36% to $361.0 million, according to results furnished with its SEC filing. Management also raised its forecast for cash use after capital spending to $205 million–$220 million, from $195 million–$205 million.
More Sales, More Spending
The new revenue outlook calls for $1.36 billion–$1.37 billion in 2026, replacing $1.34 billion–$1.36 billion. That represents expected growth of 38%–40% over 2025, versus the previous 36%–38% range.
GH shares plunged about 11% to $137.20 in Friday trading. Quarterly revenue a year earlier was $265.2 million.
The spending outlook also moved higher: management expects adjusted operating expenses of $1.105 billion–$1.125 billion, versus $1.080 billion–$1.100 billion previously. The annual adjusted gross-margin forecast is now 65%, compared with 64%–65% before.
Quarterly operating expenses reached $368.9 million, against $270.6 million a year earlier. Guardant attributed the increase principally to expanding its commercial infrastructure, marketing its screening and oncology businesses, and higher stock-based pay. Adjusted expenses rose to $287.4 million from $228.9 million.
The reported quarterly net loss widened to $124.4 million, or $0.93 per share, from $92.7 million, or $0.74. On an adjusted basis, the loss narrowed to $38.8 million, or $0.29 per share, versus $48.3 million, or $0.39.
Quarterly cash use after capital spending fell to $37.2 million from $45.8 million. Cash, cash equivalents and restricted cash totaled $1.1 billion on September 30, 2026. Adjusted gross margin—the portion of revenue left after direct costs—improved to 67% from 66%; the standard-accounting margin held at 65%.
Shield Drives Screening Growth
Screening generated $67.6 million in third-quarter revenue, up 180% from $24.1 million a year earlier. Shield volume climbed 246% to 83,000 tests, compared with 24,000.
Shield screens adults age 45 and older who have average colorectal-cancer risk. Guardant's other tests serve different stages of cancer care: Guardant360 helps select treatments for advanced cancer, while Guardant Reveal checks for residual or recurring disease in early-stage colorectal, breast and lung cancer.
Shield's commercial insurance coverage now reaches more than 80% of eligible lives, with additions including UnitedHealth Group, Carelon Healthcare Services and EviCore. Guardant also fully implemented an FDA-approved workflow designed for lower costs and greater testing throughput.
“Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives,” said AmirAli Talasaz, Guardant's co-founder and co-CEO.
Management now expects annual screening revenue of $233 million–$238 million and Shield volume of 285,000–290,000 tests. The previous ranges were $218 million–$230 million and 270,000–285,000 tests.
Oncology Volume Outpaces Revenue
Oncology revenue rose 25% to $231.3 million from $184.4 million, while test volume increased 58% to 117,000. Management expects approximately 30% oncology revenue growth for 2026 and volume growth above 50%.
Biopharma & Data revenue reached $59.0 million, up 8% from $54.7 million. Annual growth is expected to be a little over 10%. Licensing and other revenue increased to $3.1 million from $2.0 million.
Guardant360 CDx received FDA approval and European CE-marking for use with AstraZeneca's ETCAMAH, or camizestrant, including repeated breast-cancer testing. The FDA also approved the test for eligible patients with ESR1-mutated advanced or metastatic breast cancer receiving INLURIYO, or imlunestrant, with VERZENIO, or abemaciclib.
Guardant submitted an FDA approval application for Guardant360 Tissue and launched Guardant Reveal Ultra with biopharma partners.
Guardant says Guardant Reveal Ultra remains on track for a clinical launch in 2026.
Sources
- 8-K Filing — Guardant Health, Inc. (GH) — SEC EDGAR
- Exhibit gh-09302026xexhibit991.htm — Guardant Health, Inc. 8-K exhibit — SEC EDGAR
- Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates — Yahoo Finance
- Guardant Health: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36% as Shield ... — Yahoo Finance
- Guardant raises FY2026 revenue guidance to $1.36B-$1.37B while targeting Shield cost per test of $200 by end of 2028 (NASDAQ:GH) | Seeking Alpha — seekingalpha.com
- Guardant Health (GH) Could Be 17% Undervalued As Board Appointment Tests Valuation — Yahoo Finance